Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

IF 3.3 4区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Neuroendocrinology Pub Date : 2024-09-11 DOI:10.1111/jne.13442

Shiwei Guo, Heshui Wu, Suizhi Gao, Weiyu Hu, Hui Jiang, Yun Bian, Yijie Zhang, Bo Li, Gang Li, Xuefeng Xu, Min Wang, Chenglin Zhu, Linlin Qu, Qiang Huang, Renyi Qin, Wenhui Lou, Gang Jin

{"title":"Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study","authors":"Shiwei Guo, Heshui Wu, Suizhi Gao, Weiyu Hu, Hui Jiang, Yun Bian, Yijie Zhang, Bo Li, Gang Li, Xuefeng Xu, Min Wang, Chenglin Zhu, Linlin Qu, Qiang Huang, Renyi Qin, Wenhui Lou, Gang Jin","doi":"10.1111/jne.13442","DOIUrl":null,"url":null,"abstract":"Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence‐based data and remains controversial. This study aimed to validate whether long‐acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real‐world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted. Propensity score matching and inverse probability of treatment weight analysis were used to control confounding factors. Overall, 357 patients (octreotide group, n = 82; control group, n = 275) were analyzed. Kaplan–Meier survival analyses showed that the octreotide group had longer disease‐free survival (DFS) compared with the control group (36 months: 93.3% vs. 79.0%, p = .0124; 60 months: 71% vs. 67.6%, p = .0596, respectively), as well as overall survival (OS) (60 months: 98% vs. 83.8%, p = .0117, respectively). Multivariate analyses indicated that octreotide long‐acting repeatable (LAR) adjuvant therapy was associated with higher OS (p = .0270) at 60 months. Propensity score matching analysis showed that octreotide adjuvant therapy was associated with higher DFS (p = .0455) and OS (p = .0190) at 60 months. Similar results were obtained via inverse probability of treatment weight analysis. Subgroup analysis indicated that octreotide LAR was associated with a high DFS in patients with lymph node metastasis or Ki‐67 <10% PanNETs. Adjuvant therapy with long‐acting octreotide following radical resection of nonmetastatic G2 PanNETs may be associated with improved DFS and OS in a real‐world setting.","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jne.13442","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence‐based data and remains controversial. This study aimed to validate whether long‐acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real‐world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted. Propensity score matching and inverse probability of treatment weight analysis were used to control confounding factors. Overall, 357 patients (octreotide group, n = 82; control group, n = 275) were analyzed. Kaplan–Meier survival analyses showed that the octreotide group had longer disease‐free survival (DFS) compared with the control group (36 months: 93.3% vs. 79.0%, p = .0124; 60 months: 71% vs. 67.6%, p = .0596, respectively), as well as overall survival (OS) (60 months: 98% vs. 83.8%, p = .0117, respectively). Multivariate analyses indicated that octreotide long‐acting repeatable (LAR) adjuvant therapy was associated with higher OS (p = .0270) at 60 months. Propensity score matching analysis showed that octreotide adjuvant therapy was associated with higher DFS (p = .0455) and OS (p = .0190) at 60 months. Similar results were obtained via inverse probability of treatment weight analysis. Subgroup analysis indicated that octreotide LAR was associated with a high DFS in patients with lymph node metastasis or Ki‐67 <10% PanNETs. Adjuvant therapy with long‐acting octreotide following radical resection of nonmetastatic G2 PanNETs may be associated with improved DFS and OS in a real‐world setting.

查看原文本刊更多论文

奥曲肽辅助治疗对高复发风险胰腺神经内分泌肿瘤患者的实际疗效：多中心回顾性队列研究

胰腺神经内分泌肿瘤（PanNET）根治性切除术后的辅助治疗缺乏循证数据，仍存在争议。本研究旨在通过聚类真实世界的数据，验证长效奥曲肽是否是G2 PanNET高复发风险患者辅助治疗的潜在候选药物。研究对2008年至2020年间在六个研究中心接受根治性切除术的非转移性2级PanNET患者进行了回顾性研究。采用倾向评分匹配和治疗权重逆概率分析来控制混杂因素。总共分析了357名患者（奥曲肽组，n = 82；对照组，n = 275）。卡普兰-梅耶生存分析显示，与对照组相比，奥曲肽组的无病生存期（DFS）更长（36 个月：93.3% 对 79.3%）：93.3% vs. 79.0%，p = .0124；60 个月：71% vs. 67.6%，p = .0124；60 个月：71% vs. 67.6%，p = .0124：分别为 71% vs. 67.6%，p = .0596），以及总生存期（OS）（60 个月：分别为 98% vs. 83.8%，p = .0117）。多变量分析表明，奥曲肽长效重复（LAR）辅助治疗与60个月时较高的OS相关（p = .0270）。倾向评分匹配分析显示，奥曲肽辅助治疗与60个月时较高的DFS（p = .0455）和OS（p = .0190）相关。通过治疗权重的逆概率分析也得到了类似的结果。亚组分析表明，在淋巴结转移或Ki-67 <10% PanNETs患者中，奥曲肽LAR与较高的DFS相关。在现实世界中，非转移性G2 PanNET根治性切除术后使用长效奥曲肽进行辅助治疗可能会改善DFS和OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroendocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

6.20%

发文量

137

审稿时长

4-8 weeks

期刊介绍： Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.